Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Single-arm, Multi-center, Phase 2 Study to Evaluate SHR-1210(Anti-PD-1 Antibody) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Next Previous
X
Search
Trial Profile

An Open-label, Single-arm, Multi-center, Phase 2 Study to Evaluate SHR-1210(Anti-PD-1 Antibody) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Jiangsu Hengrui Medicine Co.

    • Most Recent Events

    • 14 Feb 2023 Status changed from completed to active, no longer recruiting.
    • 14 Feb 2023 Planned End Date changed from 1 Jun 2019 to 20 Aug 2023.
    • 01 Jun 2022 Primary endpoint (Objective response rate) has been met, according to Results published in the Cancer Immunology Immunotherapy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top